Hypofractionated radiotherapy combined with a PD-1 inhibitor, granulocyte macrophage-colony stimulating factor, and thymosin-α1 in advanced metastatic solid tumors: a multicenter Phase II clinical trial

An independent multicenter study examined a related four-component radioimmunotherapy strategy.

Cancer immunology, immunotherapy : CII · Feb 4, 2025
Original authors: Jiamin Yu, Li Yin, Wenjie Guo, Qiang Wang, Juying Liu, Lansheng Zhang, Hongxun Ye, Jianhong Xia, Youyou Xia, Jianfeng Wu, Wanwei Wang, Yanguang Yang, Dan Zong, Xia He, Lijun Wang, Hong Jiang

Related research: included for context and not presented as a PRaG-series trial.

Who was studied?

37 heavily pretreated patients with metastatic solid tumors enrolled across centers.

What does the publication report?

Median PFS in the ITT population was 3.5 months. Reported ORR was 23.08% and DCR 65.38%; response denominators require full-text context. OS was immature.

Safety findings

Six grade 3 or 4 adverse events were reported; no grade 5 events were reported.

How should we interpret it?

Small nonrandomized cohort with short follow-up. Do not equate this independent regimen with PRaG 5.0.

Read the original source

This independently written summary was checked against the publicly available abstract. It is not a translation of the full paper or a clinical recommendation.

Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.